Welcome to our dedicated page for Karyopharm Therapeutics SEC filings (Ticker: KPTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Karyopharm Therapeutics Inc. (KPTI) SEC filings page provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Karyopharm is a commercial-stage pharmaceutical company listed on the Nasdaq Global Select Market, and its filings detail financial results, financing arrangements and key corporate developments related to its oncology-focused business.
Among the most relevant documents for investors are Form 10-K annual reports and Form 10-Q quarterly reports, which summarize financial performance, risk factors and updates on Karyopharm’s commercial product XPOVIO (selinexor) and its clinical pipeline in multiple myeloma, endometrial cancer, myelofibrosis and diffuse large B-cell lymphoma (DLBCL). These periodic reports typically discuss revenue from U.S. XPOVIO net product sales and license and royalty revenue from partners, as described in the company’s public communications.
The company also files numerous Form 8-K current reports to describe material events. Recent 8-K filings referenced in the provided information include disclosures of quarterly financial results, strategic financing transactions involving senior secured term loans and 9.00% convertible senior notes due 2028 and 2029, and the issuance of equity and warrants in private placements. Other 8-Ks cover topics such as board changes, workforce reductions and the provision of “cleansing materials” to potential investors during financing discussions.
Investors tracking capital structure and liquidity can review exhibits to these filings, which describe credit and guaranty agreements, note purchase agreements, warrant terms and registration rights agreements. For governance and compensation matters, additional filings may include proxy statements and equity award disclosures, such as inducement grants reported under Nasdaq Listing Rule 5635(c)(4).
On this page, Stock Titan supplements raw EDGAR documents with AI-powered summaries that highlight the main points of lengthy filings, helping readers quickly understand changes in debt, equity, cash runway expectations, and updates on Karyopharm’s clinical and commercial programs. Real-time updates ensure that new 10-Ks, 10-Qs, 8-Ks and other forms appear as they are filed, while specialized views can surface insider-related forms such as Form 4 when available.
Karyopharm Therapeutics (KPTI)12,799 restricted stock units (RSUs) on October 15, 2025 at a stated price of $0. The RSUs convert into common stock on a one-for-one basis.
According to the award terms, 2,799 RSUs vest in two equal annual installments beginning October 31, 2026, and 10,000 RSUs vest 100% on October 15, 2026. Following this award, Abate beneficially owned 22,845 shares, reported as Direct (D) ownership.
Karyopharm Therapeutics (KPTI) completed a set of financing transactions. The company issued 9.00% senior secured convertible notes in two series: $15.0 million aggregate principal amount due 2028 and $103.5 million aggregate principal amount due 2029. It also borrowed $12.5 million under its existing credit and guaranty agreement.
The company entered into indentures for each note series with Wilmington Savings Fund Society as trustee and collateral agent and executed related registration rights agreements with term loan lenders. Exhibits include a first amendment and waiver to the credit agreement, a note purchase agreement, exchange agreements, warrant forms, a pre-funded warrant form, and a sixth amendment to the revenue interest financing agreement.
Shares outstanding were 15,926,939 as of October 14, 2025, assuming no exercise of pre-funded warrants or warrants and no conversions of the new convertible notes.
Karyopharm Therapeutics, Inc. disclosed an amendment and related licensing activity centered on its oncology drug selinexor. Under an Amendment No. 4 dated
Karyopharm Therapeutics (KPTI) reported an insider transaction by its Chief Accounting Officer, Kristin Abate. On 10/01/2025, Abate sold 362 shares of common stock at a weighted average price of $6.296. Following the sale, she beneficially owned 10,046 shares directly.
According to the filing, the broker-assisted sale was executed under a durable automatic sale instruction plan adopted on May 27, 2021, to satisfy withholding taxes upon the vesting of PSUs, and does not represent a discretionary trade.
Richard A. Paulson, President, CEO and a director of Karyopharm Therapeutics (KPTI), reported the vesting of 2,800 performance-based restricted stock units (PSUs) on September 12, 2025. These PSUs were granted in February 2023 and were earned after the Compensation Committee certified completion of enrollment in the company’s Phase 3 SENTRY trial; each earned PSU represents the contingent right to one share and vested upon certification. Following vesting, a broker-assisted sale executed under an automatic sale instruction plan sold 1,257 shares on September 15, 2025 at $6.43 per share to satisfy withholding tax obligations. After these transactions, the reporting person beneficially owned 84,046 shares.
Michael Mano, SVP, General Counsel & Secretary of Karyopharm Therapeutics (KPTI), reported that 612 performance-based restricted stock units (PSUs) were certified as earned and vested following achievement of a clinical enrollment milestone for the company’s Phase 3 SENTRY trial, converting into the contingent right to the same number of common shares. To satisfy tax withholding on the vested PSUs, the reporting person executed a broker-assisted sale of 234 shares at an average price of $6.43, leaving beneficial ownership of 21,425 shares.
Stuart Poulton, EVP and Chief Development Officer of Karyopharm Therapeutics (KPTI), reported the vesting of 888 performance-based restricted stock units (PSUs) on 09/12/2025 after the company certified completion of enrollment in its Phase 3 SENTRY trial. Each PSU converts to one share, increasing his beneficial ownership to 28,111 shares. On 09/15/2025 he executed an automatic, broker-assisted sale of 401 shares at $6.43 to cover withholding taxes, leaving 27,710 shares beneficially owned. The PSUs were originally granted in February 2023 and vested upon certification by the Compensation Committee. The Form 4 was signed by an attorney-in-fact on 09/16/2025.
Insider filings show that Reshma Rangwala, EVP & Chief Medical Officer of Karyopharm Therapeutics (KPTI), had performance-based restricted stock units (PSUs) certified as earned and vested on September 12, 2025. The certification converted 945 PSUs into the contingent right to receive 945 shares of common stock, increasing her beneficial holdings to 29,798 shares. Three days later, on September 15, 2025, Rangwala executed a broker-assisted sale of 408 shares at $6.43 per share under an automatic sale instruction plan to satisfy withholding tax liabilities related to the PSU vesting, leaving her with 29,390 shares beneficially owned.
Sohanya Cheng, EVP & Chief Commercial Officer of Karyopharm Therapeutics (KPTI), reported the vesting of performance-based restricted stock units tied to a clinical enrollment milestone and a subsequent small sale to cover taxes. The issuer certified that PSUs granted in February 2023 were earned based on achieving complete enrollment in the company\'s Phase 3 SENTRY trial; 945 earned PSUs vested and each represents the right to one common share. Following vesting, the reporting person beneficially owned 36,181 shares, which includes 922 shares purchased under the company\'s employee stock purchase plan. A broker-assisted sale of 325 shares at $6.43 per share was executed under an automatic sale instruction to satisfy withholding tax obligations incurred on the vested PSUs.
Kristin Abate, Chief Accounting Officer of Karyopharm Therapeutics Inc. (KPTI), reported the vesting of performance-based restricted stock units and a small subsequent sale. On September 12, 2025 the company certified that the clinical milestone for complete enrollment in its Phase 3 SENTRY trial had been achieved, resulting in 46 earned PSUs (each convertible into one share) which vested that day. The reporting line shows 10,431 shares beneficially owned following vesting (including 922 shares acquired via the ESPP on April 30, 2025). On September 15, 2025 the reporting person sold 23 shares at $6.43 per share under a pre-established automatic sale instruction to satisfy tax withholding obligations.